Articles From: Elephant Talk Receives $10 Million Service Prepayment as part of New 5 Year Contract with Existing MNO Client in Europe to Eli Lilly Says New Product Doesn't Infringe Patents


2013/12/13
Increased capabilities positions the Software-DNA™platform for the roll out to other geographies OKLAHOMA CITY , Dec.
Sign-up for Elephant Talk Receives $10 Million Service Prepayment as part of New 5 Year Contract with Existing MNO Client in Europe investment picks
2014/3/26
Fourth Quarter Revenue increased $800,000 or 16% compared to the Third Quarter of 2013; 2013 Fourth Quarter Margins were over 82%; Achieved Positive Adjusted EBITDA in the Fourth Quarter of 2013 OKLAHOMA CITY , March 26, 2014 /PRNewswire/ -- Elephant Talk Communications Corp.
Sign-up for Elephant Talk Reports 2013 Fourth Quarter and Year End Financial Results investment picks
2014/2/25
Initial customer migration is the first segment of 8 million subscribers planned to migrate in 2014 MEXICO CITY and OKLAHOMA CITY , Feb.
Sign-up for Elephant Talk Successfully Migrates 600,000+ Iusacell Subscribers in Mexico onto its Software DNA™ 2.0 Platform investment picks
2014/3/13
OKLAHOMA CITY , March 13, 2014 /PRNewswire/ -- Elephant Talk Communications Corp.
Sign-up for Elephant Talk to Host 2013 Year End Financial Results Conference Call on March 18th at 11:00 a.m. ET investment picks
OKLAHOMA CITY , Aug.
Sign-up for Elephant Talk to Host Second Quarter Shareholder Update Call on August 8, 2013 investment picks
OKLAHOMA CITY , Sept.
Sign-up for Elephant Talk to Present at the LD MICRO Conference on October 2, 2013 investment picks
2013/10/18
By John Revill ZURICH--Schindler Holding AG (SCHN.EB) shares rose nearly 5% in early trading Friday after the elevator-and-escalator maker launched a 1 billion Swiss franc ($1.1 billion) securities buyback.
Sign-up for Elevator Maker Schindler Lifts Share Price With Buyback investment picks
2014/4/1
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has been added as a member of the Russell 2000® and Russell 3000® Indexes after the close of market yesterday, March 31, 2014.
Sign-up for Eleven Biotherapeutics Added to Russell Indexes on March 31, 2014 investment picks
2014/3/3
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company’s board of directors.
Sign-up for Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors investment picks
2014/2/11
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions, including 750,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to cover over-allotments.
Sign-up for Eleven Biotherapeutics Closes Initial Public Offering investment picks
2014/2/18
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company’s first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, D o uble-Masked, Randomized, Controlled, Efficacy a nd S afety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control  I n Subjects With Moderate to S evere Dry Eye Disease). EBI-005, the Company’s most advanced product candidate generated using its AMP-Rx platform, is a novel, topically administered Interleukin-1 (IL-1) receptor blocker currently in development for the treatment of dry eye disease and allergic conjunctivitis.
Sign-up for Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease investment picks
2014/2/6
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.
Sign-up for Eleven Biotherapeutics Prices Initial Public Offering investment picks
2014/3/4
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it received a no-objection letter from Health Canada and that patient dosing is underway in the Company’s Phase 2 clinical trial of EBI-005 for the treatment of allergic conjunctivitis (AC). EBI-005, the Company’s most advanced product candidate generated using its AMP-Rx platform, is a novel, topically administered Interleukin-1 (IL-1) receptor blocker.
Sign-up for Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005 investment picks
2014/2/26
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., Eleven’s President and CEO, is scheduled to present at the following healthcare conferences during March 2014.
Sign-up for Eleven Biotherapeutics to Present at March Healthcare Conferences investment picks
2014/3/20
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that three poster presentations demonstrating the key role of cytokine biology to effectively target both front and back of eye diseases, including clinical data on its lead drug candidate EBI-005 and preclinical data on EBI-029 have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting taking place May 4-8, 2014, in Orlando, FL.
Sign-up for Eleven Biotherapeutics to Present Data on Product Candidates at the ARVO 2014 Annual Meeting investment picks
2014/4/3
LONDON , April 3, 2014 /PRNewswire/ -- Global communications leader Porter Novelli announced today it has been shortlisted for eleven nominations for the EMEA SABRE Gold and Diamond Awards.
Sign-up for Eleven Porter Novelli Campaigns Shortlisted for EMEA SABRE Awards investment picks
ACTON, Mass., Aug.
Sign-up for Eleven Video Service Providers Select SeaChange Content Management Solutions investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0889399001&sourceType=1 http://media3.marketwire.com/logos/20120201-elgin-logo.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Elgin Mining Announces Second Quarter 2013 Conference Call Details investment picks
2014/3/3
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0931124001&sourceType=1 http://media3.marketwire.com/logos/20120201-elgin-logo.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Elgin Mining Provides Strong Fourth Quarter Cash Costs and Positive 2014 Outlook investment picks
2013/8/12
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0891832001&sourceType=1 http://media3.marketwire.com/logos/20120201-elgin-logo.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Elgin Mining Reports Second Quarter 2013 Results investment picks
2013/11/12
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0910899001&sourceType=1 http://media3.marketwire.com/logos/20120201-elgin-logo.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Elgin Mining Reports Third Quarter 2013 Results investment picks
2013/9/30
By Nathalie Tadena Eli Lilly & Co.
Sign-up for Eli Lilly 'Disappointed' in CMS Decision on Amyvid investment picks
By Nathalie Tadena Eli Lilly & Co.'s (LLY) third-quarter earnings fell 9.3% as the year-ago period included a one-time payment from a former partner.
Sign-up for Eli Lilly 3rd-Quarter Profit Down 9.3%, Revenue Rises investment picks
2013/12/20
New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency INDIANAPOLIS and RIDGEFIELD, Conn.
Sign-up for Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product investment picks
- Prasco to market the Authorized Generic of EVISTA® in the United States CINCINNATI , April 1, 2014 /PRNewswire/ --  Prasco Laboratories , announced today it has signed a marketing and distribution agreement with  Eli Lilly and Company   (NYSE: LLY) to market the Authorized Generic (AG) version of EVISTA ® (raloxifene hydrochloride tablets), in 60 mg strength in the United States.
Sign-up for Eli Lilly and Company Expands Authorized Generic Agreements with Prasco® investment picks
2014/1/31
INDIANAPOLIS , Jan.
Sign-up for Eli Lilly and Company Provides Statement in Response to Sanofi U.S. Lawsuit investment picks
NEW YORK (MarketWatch) -- Analysts at Jefferies downgraded three major pharmaceutical companies Friday, citing deteriorating business fundamentals.
Sign-up for Eli Lilly downgraded to underperform by Jefferies investment picks
By Ben Fox Rubin Eli Lilly & Co.
Sign-up for Eli Lilly Profit Drops After Cymbalta Patent Expiration investment picks
2014/1/30
By Peter Loftus Eli Lilly & Co.
Sign-up for Eli Lilly Profit Drops; Sanofi Files Patent Suit Vs Co. -- 2nd Update investment picks
2014/1/31
By John Kell Eli Lilly & Co., facing a lawsuit by Sanofi SA, said it doesn't believe one of its proposed new insulin products infringes upon patents covering Sanofi's Lantus insulin.
Sign-up for Eli Lilly Says New Product Doesn't Infringe Patents investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Elephant Talk Receives $10 Million Service Prepayment as part of New 5 Year Contract with Existing MNO Client in Europe to Eli Lilly Says New Product Doesn't Infringe Patents
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity